Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 51

Cited In for PubMed (Select 10910043)

1.

OCAM Regulates Embryonic Spinal Cord Stem Cell Proliferation by Modulating ErbB2 Receptor.

Deleyrolle L, Sabourin JC, Rothhut B, Fujita H, Guichet PO, Teigell M, Ripoll C, Chauvet N, Perrin F, Mamaeva D, Noda T, Mori K, Yoshihara Y, Hugnot JP.

PLoS One. 2015 Apr 13;10(4):e0122337. doi: 10.1371/journal.pone.0122337. eCollection 2015.

2.

Mild hyperthermia influence on Herceptin(®) properties.

Escoffre JM, Deckers R, Sasaki N, Bos C, Moonen C.

Radiol Oncol. 2015 Mar 3;49(1):41-9. doi: 10.2478/raon-2014-0045. eCollection 2015 Mar.

3.

The Mysterious Ways of ErbB2/HER2 Trafficking.

Bertelsen V, Stang E.

Membranes (Basel). 2014 Aug 6;4(3):424-46. doi: 10.3390/membranes4030424. Review.

4.

"PEST control": regulation of molecular barcodes by tyrosine phosphatases.

Doody KM, Bottini N.

Cell Res. 2014 Sep;24(9):1027-8. doi: 10.1038/cr.2014.100. Epub 2014 Aug 1.

PMID:
25081059
5.

The catalytic region and PEST domain of PTPN18 distinctly regulate the HER2 phosphorylation and ubiquitination barcodes.

Wang HM, Xu YF, Ning SL, Yang DX, Li Y, Du YJ, Yang F, Zhang Y, Liang N, Yao W, Zhang LL, Gu LC, Gao CJ, Pang Q, Chen YX, Xiao KH, Ma R, Yu X, Sun JP.

Cell Res. 2014 Sep;24(9):1067-90. doi: 10.1038/cr.2014.99. Epub 2014 Aug 1.

6.

Trastuzumab-induced recruitment of Csk-homologous kinase (CHK) to ErbB2 receptor is associated with ErbB2-Y1248 phosphorylation and ErbB2 degradation to mediate cell growth inhibition.

Dokmanovic M, Wu Y, Shen Y, Chen J, Hirsch DS, Wu WJ.

Cancer Biol Ther. 2014 Aug;15(8):1029-41. doi: 10.4161/cbt.29171. Epub 2014 May 16.

PMID:
24835103
7.

Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2.

Maron R, Schechter B, Mancini M, Mahlknecht G, Yarden Y, Sela M.

Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15389-94. doi: 10.1073/pnas.1313857110. Epub 2013 Sep 3.

8.

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.

Oncogene. 2014 Jun 26;33(26):3422-31. doi: 10.1038/onc.2013.308. Epub 2013 Aug 5.

9.

Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance.

Chung A, Cui X, Audeh W, Giuliano A.

Clin Breast Cancer. 2013 Aug;13(4):223-32. doi: 10.1016/j.clbc.2013.04.001. Review.

10.

Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway.

Kuo HP, Hsu SC, Ou CC, Li JW, Tseng HH, Chuang TC, Liu JY, Chen SJ, Su MH, Cheng YC, Chou WY, Kao MC.

Evid Based Complement Alternat Med. 2013;2013:219472. doi: 10.1155/2013/219472. Epub 2013 Apr 7.

11.

Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth.

Mahlknecht G, Maron R, Mancini M, Schechter B, Sela M, Yarden Y.

Proc Natl Acad Sci U S A. 2013 May 14;110(20):8170-5. doi: 10.1073/pnas.1302594110. Epub 2013 Apr 29.

12.

Gastric cancer and trastuzumab: first biologic therapy in gastric cancer.

Gunturu KS, Woo Y, Beaubier N, Remotti HE, Saif MW.

Ther Adv Med Oncol. 2013 Mar;5(2):143-51. doi: 10.1177/1758834012469429.

13.

Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases.

Kong F, Zhang J, Li Y, Hao X, Ren X, Li H, Zhou P.

Oncogene. 2014 Feb 20;33(8):986-95. doi: 10.1038/onc.2013.33. Epub 2013 Feb 18.

14.

From bortezomib to other inhibitors of the proteasome and beyond.

Buac D, Shen M, Schmitt S, Kona FR, Deshmukh R, Zhang Z, Neslund-Dudas C, Mitra B, Dou QP.

Curr Pharm Des. 2013;19(22):4025-38. Review.

15.
16.

Trastuzumab: updated mechanisms of action and resistance in breast cancer.

Vu T, Claret FX.

Front Oncol. 2012 Jun 18;2:62. doi: 10.3389/fonc.2012.00062. eCollection 2012.

17.

Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand.

Vaidyanath A, Hashizume T, Nagaoka T, Takeyasu N, Satoh H, Chen L, Wang J, Kasai T, Kudoh T, Satoh A, Fu L, Seno M.

J Cell Mol Med. 2011 Nov;15(11):2525-38. doi: 10.1111/j.1582-4934.2011.01277.x.

18.

Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients.

Scaltriti M, Eichhorn PJ, Cortés J, Prudkin L, Aura C, Jiménez J, Chandarlapaty S, Serra V, Prat A, Ibrahim YH, Guzmán M, Gili M, Rodríguez O, Rodríguez S, Pérez J, Green SR, Mai S, Rosen N, Hudis C, Baselga J.

Proc Natl Acad Sci U S A. 2011 Mar 1;108(9):3761-6. doi: 10.1073/pnas.1014835108. Epub 2011 Feb 14.

19.

Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.

Patani N, Jiang W, Newbold R, Mokbel K.

J Carcinog. 2010 Nov 12;9:9. doi: 10.4103/1477-3163.72505.

20.

Ubiquitination-dependent regulation of signaling receptors in cancer.

Huangfu WC, Fuchs SY.

Genes Cancer. 2010 Jul;1(7):725-34. doi: 10.1177/1947601910382901.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk